AU2007319209B2 - Arylsulfonamide compounds - Google Patents

Arylsulfonamide compounds Download PDF

Info

Publication number
AU2007319209B2
AU2007319209B2 AU2007319209A AU2007319209A AU2007319209B2 AU 2007319209 B2 AU2007319209 B2 AU 2007319209B2 AU 2007319209 A AU2007319209 A AU 2007319209A AU 2007319209 A AU2007319209 A AU 2007319209A AU 2007319209 B2 AU2007319209 B2 AU 2007319209B2
Authority
AU
Australia
Prior art keywords
compound
alkyl
compound according
alkenyl
raryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2007319209A
Other languages
English (en)
Other versions
AU2007319209A1 (en
Inventor
Jonathan Bayldon Baell
Wayne J. Fairbrother
John A. Flygare
Michael F. T. Koehler
Guillaume Laurent Lessene
Brad Edmund Sleebs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Walter and Eliza Hall Institute of Medical Research
Genentech Inc
Original Assignee
Walter and Eliza Hall Institute of Medical Research
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Walter and Eliza Hall Institute of Medical Research, Genentech Inc filed Critical Walter and Eliza Hall Institute of Medical Research
Publication of AU2007319209A1 publication Critical patent/AU2007319209A1/en
Assigned to THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH, GENENTECH, INC. reassignment THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH Alteration of Name(s) of Applicant(s) under S113 Assignors: GENENTECH, INC., WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH
Application granted granted Critical
Publication of AU2007319209B2 publication Critical patent/AU2007319209B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AU2007319209A 2006-11-15 2007-11-15 Arylsulfonamide compounds Active AU2007319209B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85931506P 2006-11-15 2006-11-15
US60/859,315 2006-11-15
PCT/US2007/084873 WO2008061208A2 (en) 2006-11-15 2007-11-15 Arylsulfonamide compounds

Publications (2)

Publication Number Publication Date
AU2007319209A1 AU2007319209A1 (en) 2008-05-22
AU2007319209B2 true AU2007319209B2 (en) 2012-04-19

Family

ID=39276199

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007319209A Active AU2007319209B2 (en) 2006-11-15 2007-11-15 Arylsulfonamide compounds

Country Status (9)

Country Link
US (1) US8168645B2 (enExample)
EP (1) EP2094672B1 (enExample)
JP (1) JP5366817B2 (enExample)
CN (1) CN101535280B (enExample)
AU (1) AU2007319209B2 (enExample)
CA (1) CA2666837C (enExample)
ES (1) ES2423029T3 (enExample)
NZ (1) NZ577442A (enExample)
WO (1) WO2008061208A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009085216A2 (en) 2007-12-20 2009-07-09 Squicor Compositions and methods for detecting or elimninating senescent cells to diagnose or treat disease
SG187502A1 (en) 2008-02-01 2013-02-28 Takeda Pharmaceutical Oxim derivatives as hsp90 inhibitors
CN102105449A (zh) * 2008-05-21 2011-06-22 健泰科生物技术公司 芳基磺酰胺化合物、组合物及其使用方法
US8168784B2 (en) * 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
CA2772989A1 (en) * 2009-09-10 2011-03-17 Novartis Ag Sulfonamides as inhibitors of bcl-2 family proteins for the treatment of cancer
TWI535712B (zh) * 2010-08-06 2016-06-01 阿斯特捷利康公司 化合物
WO2012177927A1 (en) 2011-06-21 2012-12-27 Mayo Foundation For Medical Education And Research Transgenic animals capable of being induced to delete senescent cells
MX2014007093A (es) 2011-12-13 2014-10-13 Buck Inst For Res On Aging Metodos para mejorar terapias medicas.
US9126980B2 (en) 2011-12-23 2015-09-08 Novartis Ag Compounds for inhibiting the interaction of BCL2 with binding partners
EP2794591A1 (en) 2011-12-23 2014-10-29 Novartis AG Compounds for inhibiting the interaction of bcl2 with binding partners
US20150064137A1 (en) 2012-04-17 2015-03-05 Kythera Biopharmaceuticals, Inc. Use of engineered viruses to specifically kill senescent cells
US9901080B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells
US9901081B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse for determining the role of senescent cells in cancer
US20170216286A1 (en) 2014-01-28 2017-08-03 Mayo Foundation For Medical Education And Research Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid
US20190269675A1 (en) 2014-01-28 2019-09-05 Buck Institute for Research and Aging Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents
US10328058B2 (en) 2014-01-28 2019-06-25 Mayo Foundation For Medical Education And Research Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques
IL286427B2 (en) 2014-01-28 2024-08-01 Mayo Found Medical Education & Res Inhibitors bcl-2 anti-apoptotic protein family members for treatment of non cancer pulmonary disease or an opthalmic disease
US10195213B2 (en) 2015-03-13 2019-02-05 Unity Biotechnology, Inc. Chemical entities that kill senescent cells for use in treating age-related disease
TWI773730B (zh) 2017-02-22 2022-08-11 瑞典商阿斯特捷利康公司 治療性樹枝狀聚合物
KR20200108301A (ko) 2018-01-10 2020-09-17 리커리엄 아이피 홀딩스, 엘엘씨 벤즈아미드 화합물
CN108276395B (zh) * 2018-02-09 2021-02-26 合肥华方医药科技有限公司 一种多沙唑嗪杂质的制备方法
CN108570039B (zh) * 2018-04-25 2022-09-23 上海美迪西生物医药股份有限公司 一类具有抑制抗凋亡蛋白活性的化合物及其制备和应用
CN109851535A (zh) * 2019-01-30 2019-06-07 天津现代职业技术学院 一种制备4-氟-3-(三氟甲磺酰基)苯磺酰胺的方法
CN113248415B (zh) * 2021-05-26 2022-08-09 苏州正永生物医药有限公司 一种abt-737关键中间体的制备方法以及abt-737的制备方法
PT4426434T (pt) 2021-11-02 2025-11-24 Flare Therapeutics Inc Agonistas inversos de pparg e suas utilizações

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003080586A1 (en) * 2002-03-21 2003-10-02 Abbott Laboratories N-sulfonylurea apoptosis promoters
US20060084647A1 (en) * 2004-08-20 2006-04-20 Regents Of The University Of Michigan Small molecule inhibitors of anti-apoptotic BCL-2 family members and the uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6720338B2 (en) 2000-09-20 2004-04-13 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US8614318B2 (en) * 2003-11-13 2013-12-24 Abbvie Inc. Apoptosis promoters
WO2005049593A2 (en) * 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US7642260B2 (en) * 2003-11-13 2010-01-05 Abbott Laboratories, Inc. Apoptosis promoters
US7767684B2 (en) * 2003-11-13 2010-08-03 Abbott Laboratories Apoptosis promoters
DE602004025494D1 (de) 2003-11-20 2010-03-25 Mitsubishi Gas Chemical Co Flüssiges cyclohexantricarbonsäureanhydrid
ATE542796T1 (de) * 2004-05-26 2012-02-15 Abbott Lab N-sulfonylcarboximidamidverbindungen als apoptosepromotoren
US8101619B2 (en) * 2004-12-08 2012-01-24 Solvay Pharmaceuticals B.V. Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition
PL1888550T3 (pl) * 2005-05-12 2014-12-31 Abbvie Bahamas Ltd Promotory apoptozy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003080586A1 (en) * 2002-03-21 2003-10-02 Abbott Laboratories N-sulfonylurea apoptosis promoters
US20060084647A1 (en) * 2004-08-20 2006-04-20 Regents Of The University Of Michigan Small molecule inhibitors of anti-apoptotic BCL-2 family members and the uses thereof

Also Published As

Publication number Publication date
HK1134283A1 (en) 2010-04-23
US8168645B2 (en) 2012-05-01
JP5366817B2 (ja) 2013-12-11
JP2010510237A (ja) 2010-04-02
CA2666837A1 (en) 2008-05-22
NZ577442A (en) 2012-02-24
WO2008061208A3 (en) 2008-07-03
CN101535280A (zh) 2009-09-16
EP2094672B1 (en) 2013-05-29
CN101535280B (zh) 2012-06-27
CA2666837C (en) 2015-01-13
US20100056517A1 (en) 2010-03-04
WO2008061208A2 (en) 2008-05-22
ES2423029T3 (es) 2013-09-17
AU2007319209A1 (en) 2008-05-22
EP2094672A2 (en) 2009-09-02

Similar Documents

Publication Publication Date Title
AU2007319209B2 (en) Arylsulfonamide compounds
ES2855135T3 (es) Amidas heterocíclicas como inhibidores de quinasa
ES2914099T3 (es) Inhibidores novedosos de ULK1 y métodos de uso de los mismos
AU2013300344B2 (en) N2,N4-bis(4-(piperazine-1-yl)phenyl)pirimidine-2,4-diamine derivative or pharmaceutically acceptable salt thereof, and composition containing same as active ingredient for preventing or treating cancer
ES2401550T3 (es) Inhibidores de proteína cinasa y uso de los mismos
WO2017101803A1 (zh) 一种新型egfr和alk激酶的双重抑制剂
US20100197711A1 (en) Benzothiazole compounds
ES2211851T3 (es) Compuesto de benzoquinozolina farmaceuticamente activos.
WO2016022460A1 (en) Potent dual brd4-kinase inhibitors as cancer therapeutics
CN101143845B (zh) 取代喹啉甲酰胍衍生物、其制备方法及其医药用途
SK283952B6 (sk) Pyrido [2,3-D]pyrimidíny a farmaceutické kompozície na ich báze
AU2019218187B2 (en) Dioxinoquinoline compounds, preparation method and uses thereof
CA2871453A1 (en) Quinazolinedione derivative
US20190071425A1 (en) Tetrahydroisoquinolines as prmt5 inhibitors
Altıntop et al. Synthesis and evaluation of a series of 1, 3, 4-thiadiazole derivatives as potential anticancer agents
ES2905985T3 (es) Compuesto de oxazino-quinazolina y de tipo oxazino-quinazolina, método de preparación y usos de los mismos
JP5227179B2 (ja) ３，６−ジヒドロ−２−オキソ−６ｈ−１，３，４−チアジアジン誘導体
WO2018095432A1 (en) Sulfoximine, sulfonimidamide, sulfondiimine and diimidosulfonamide compounds as inhibitors of indoleamine 2, 3-dioxygenase
US20090264427A1 (en) 3-Cyanoquinolines, Methods for Preparation and Use as Insulin-like Growth Factor Inhibitors
CN111440177B (zh) 一种取代吡唑并[1,5-a]嘧啶类化合物及其制备方法和应用
ES2328929T3 (es) Dihidroquinazolinas 2-sustituidas.
JP7022454B2 (ja) ジオキシノキノリン系化合物、その調製方法および使用
Brzozowski et al. Carbonic anhydrase inhibitors. Regioselective synthesis of novel series 1-substituted 1, 4-dihydro-4-oxo-3-pyridinesulfonamides and their inhibition of the human cytosolic isozymes I and II and transmembrane cancer-associated isozymes IX and XII
HK1134283B (en) Arylsulfonamide compounds
WO1994003439A1 (en) Antiproliferative tricyclic compounds

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)